Published in Europace on March 01, 2010
Diverse Fibrosis Architecture and Premature Stimulation Facilitate Initiation of Reentrant Activity Following Chronic Atrial Fibrillation. J Cardiovasc Electrophysiol (2015) 0.86
Research priorities in sarcomeric cardiomyopathies. Cardiovasc Res (2015) 0.86
Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy patients: a systematic review. J Interv Card Electrophysiol (2015) 0.77
Impact of Cryoballoon Ablation in Hypertrophic Cardiomyopathy-related Heart Failure due to Paroxysmal Atrial Fibrillation. A Comparative Case Series. Int J Med Sci (2016) 0.75
Invasive Management of Atrial Fibrillation and the Elderly. J Atr Fibrillation (2010) 0.75
Outcomes in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a survival meta-analysis. Cardiovasc Diagn Ther (2017) 0.75
Pseudophosphorylation of cardiac myosin regulatory light chain: a promising new tool for treatment of cardiomyopathy. Biophys Rev (2017) 0.75
Atrial fibrillation as manifestation and consequence of underlying cardiomyopathies: from common conditions to genetic diseases. Heart Fail Rev (2014) 0.75
Radiofrequency catheter ablation is effective for atrial fibrillation patients with hypertrophic cardiomyopathy by decreasing left atrial pressure. J Arrhythm (2017) 0.75
Left atrial wall thickness and outcomes of catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy. J Interv Card Electrophysiol (2014) 0.75
Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J (2007) 6.34
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J (2014) 5.21
Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med (2003) 5.17
Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? J Am Coll Cardiol (2011) 4.12
Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation (2006) 3.82
Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation (2003) 3.68
Usefulness of fluorine-18 positron emission tomography/computed tomography for identification of cardiovascular implantable electronic device infections. J Am Coll Cardiol (2012) 3.56
Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. J Am Coll Cardiol (2012) 3.18
Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med (2003) 2.92
Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol (2008) 2.82
Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc (2008) 2.80
Elimination of local abnormal ventricular activities: a new end point for substrate modification in patients with scar-related ventricular tachycardia. Circulation (2012) 2.80
Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation (2012) 2.78
Epicardial ventricular tachycardia ablation a multicenter safety study. J Am Coll Cardiol (2010) 2.75
Incidence of silent cerebral thromboembolic lesions after atrial fibrillation ablation may change according to technology used: comparison of irrigated radiofrequency, multipolar nonirrigated catheter and cryoballoon. J Cardiovasc Electrophysiol (2011) 2.67
Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart J (2006) 2.59
Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation (2003) 2.56
Prevalence of silent cerebral ischemia in paroxysmal and persistent atrial fibrillation and correlation with cognitive function. J Am Coll Cardiol (2013) 2.47
Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. Circulation (2010) 2.47
Electromechanical coupling in patients with the short QT syndrome: further insights into the mechanoelectrical hypothesis of the U wave. Heart Rhythm (2007) 2.44
Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol (2005) 2.43
Cardiac remote ischaemic preconditioning reduces periprocedural myocardial infarction for patients undergoing percutaneous coronary interventions: a meta-analysis of randomised clinical trials. EuroIntervention (2014) 2.30
Clinical aspects and prognosis of Brugada syndrome in children. Circulation (2007) 2.29
Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol (2010) 2.23
Classifying fractionated electrograms in human atrial fibrillation using monophasic action potentials and activation mapping: evidence for localized drivers, rate acceleration, and nonlocal signal etiologies. Heart Rhythm (2010) 2.19
Coronary computed tomographic angiography for detection of coronary artery disease in patients presenting to the emergency department with chest pain: a meta-analysis of randomized clinical trials. Eur Heart J Cardiovasc Imaging (2012) 2.19
Catheter ablation of recurrent scar-related ventricular tachycardia using electroanatomical mapping and irrigated ablation technology: results of the prospective multicenter Euro-VT-study. J Cardiovasc Electrophysiol (2009) 2.14
Long-term follow-up of idiopathic ventricular fibrillation ablation: a multicenter study. J Am Coll Cardiol (2009) 2.12
2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. J Interv Card Electrophysiol (2012) 2.08
Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation (2011) 2.04
Atrial fibrillation ablation using a robotic catheter remote control system: initial human experience and long-term follow-up results. J Am Coll Cardiol (2008) 2.02
"Dormant" pulmonary vein conduction revealed by adenosine after ostial radiofrequency catheter ablation. J Cardiovasc Electrophysiol (2004) 2.00
Left atrial linear lesions are required for successful treatment of persistent atrial fibrillation. Eur Heart J (2008) 1.98
Unresolved issues in transcatheter atrial fibrillation ablation: silent cerebrovascular ischemias. J Cardiovasc Electrophysiol (2012) 1.98
Optimizing hemodynamics in heart failure patients by systematic screening of left ventricular pacing sites: the lateral left ventricular wall and the coronary sinus are rarely the best sites. J Am Coll Cardiol (2009) 1.98
Safety and efficacy of cryoablation of accessory pathways adjacent to the normal conduction system. J Cardiovasc Electrophysiol (2003) 1.91
Functional nature of electrogram fractionation demonstrated by left atrial high-density mapping. Circ Arrhythm Electrophysiol (2012) 1.90
The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol (2010) 1.89
Inverse relationship between fractionated electrograms and atrial fibrosis in persistent atrial fibrillation: combined magnetic resonance imaging and high-density mapping. J Am Coll Cardiol (2013) 1.88
Wolff-Parkinson-White ablation after a prior failure: a 7-year multicentre experience. Europace (2010) 1.88
Short QT syndrome: pharmacological treatment. J Am Coll Cardiol (2004) 1.87
Ablation of severe drug-resistant tachyarrhythmia during pregnancy. J Cardiovasc Electrophysiol (2010) 1.84
Long-term evaluation of atrial fibrillation ablation guided by noninducibility. Heart Rhythm (2006) 1.81
Long-term clinical results of 2 different ablation strategies in patients with paroxysmal and persistent atrial fibrillation. Circ Arrhythm Electrophysiol (2008) 1.80
Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am Coll Cardiol (2010) 1.80
Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol (2005) 1.74
Clinical predictors of termination and clinical outcome of catheter ablation for persistent atrial fibrillation. J Am Coll Cardiol (2009) 1.74
Improved outcome following restoration of sinus rhythm prior to catheter ablation of persistent atrial fibrillation: a comparative multicenter study. Heart Rhythm (2012) 1.67
Validation of novel 3-dimensional electrocardiographic mapping of atrial tachycardias by invasive mapping and ablation: a multicenter study. J Am Coll Cardiol (2013) 1.67
Morphologic analysis of left atrial anatomy by magnetic resonance angiography in patients with atrial fibrillation: a large single center experience. J Cardiovasc Electrophysiol (2011) 1.66
Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). Am J Cardiol (2006) 1.66
Risk stratification of the patients with Brugada type electrocardiogram: a community-based prospective study. Europace (2009) 1.66
The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol (2009) 1.66
Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: a meta-regression of randomized clinical trials. Atherosclerosis (2012) 1.63
Long-term efficacy and safety of two different rhythm control strategies in elderly patients with symptomatic persistent atrial fibrillation. J Cardiovasc Electrophysiol (2013) 1.60
Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. J Am Coll Cardiol (2013) 1.60
Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. Am Heart J (2011) 1.59
Biventricular stimulation improves right and left ventricular function after tetralogy of Fallot repair: acute animal and clinical studies. Heart Rhythm (2009) 1.58
Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial? J Am Coll Cardiol (2007) 1.58
Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. Arch Intern Med (2006) 1.56
Chronic atrial fibrillation ablation impact on endocrine and mechanical cardiac functions. Eur Heart J (2007) 1.53
Comparison of characteristics in responders versus nonresponders with biventricular pacing for drug-resistant congestive heart failure. Am J Cardiol (2002) 1.49
Contributions of a hemodynamic sensor embedded in an atrial lead in a porcine model. J Cardiovasc Electrophysiol (2010) 1.48
Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol (2009) 1.48
Can spinal cord stimulation reduce ventricular arrhythmias? Heart Rhythm (2012) 1.46
Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy. Am J Cardiol (2010) 1.46
Long-term follow-up of persistent atrial fibrillation ablation using termination as a procedural endpoint. Eur Heart J (2009) 1.46
Early and late outcomes in patients excluded from same-day home discharge after transradial stenting and maximal antiplatelet therapy. Catheter Cardiovasc Interv (2008) 1.45
Impact of TAVI on mitral regurgitation: a prospective echocardiographic study. Echocardiography (2012) 1.44
Intracardiac impedance monitors stroke volume in resynchronization therapy patients. Europace (2010) 1.43
Microbiologic characteristics and in vitro susceptibility to antimicrobials in a large population of patients with cardiovascular implantable electronic device infection. J Cardiovasc Electrophysiol (2011) 1.42
Validation of pixel-wise parametric mapping of myocardial blood flow with ¹³NH₃ PET in patients with hypertrophic cardiomyopathy. Eur J Nucl Med Mol Imaging (2015) 1.41
Patent foramen ovale treatment strategy: an Italian large prospective study. J Cardiovasc Med (Hagerstown) (2014) 1.41
[Doubts of the cardiologist regarding an electrocardiogram presenting QRS V1-V2 complexes with positive terminal wave and ST segment elevation. Consensus Conference promoted by the Italian Cardiology Society]. G Ital Cardiol (Rome) (2010) 1.41
Mitral isthmus ablation with and without temporary spot occlusion of the coronary sinus: a randomized clinical comparison of acute outcomes. J Cardiovasc Electrophysiol (2012) 1.40